--- title: "Cumberland Pharma | 8-K: FY2025 Revenue: USD 44.52 M" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/277685741.md" datetime: "2026-03-03T22:12:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277685741.md) - [en](https://longbridge.com/en/news/277685741.md) - [zh-HK](https://longbridge.com/zh-HK/news/277685741.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277685741.md) | [English](https://longbridge.com/en/news/277685741.md) # Cumberland Pharma | 8-K: FY2025 Revenue: USD 44.52 M Revenue: As of FY2025, the actual value is USD 44.52 M. EPS: As of FY2025, the actual value is USD -0.19. EBIT: As of FY2025, the actual value is USD -2.773 M. #### Revenue - **Fourth Quarter 2025 Net Revenues**: 坎伯兰药业 (Cumberland Pharmaceuticals Inc.) reported net revenues of $13.7 million for the fourth quarter of 2025, representing a 31% increase over the prior year period . - **Full Year 2025 Net Revenues**: Net revenues for the full year 2025 were $44.5 million, an 18% increase over the prior year, meeting the company’s double-digit revenue growth target . This compares to $37,867,945 in net revenues for the full year 2024 . - **2025 Product-Specific Net Revenues**: The 2025 net revenues included $10.5 million for Kristalose®, $11.9 million for Sancuso®, $9.5 million for Vibativ®, $4.7 million for Caldolor®, and $3.3 million for Talicia® . #### Operational Metrics - **Net Loss**: The net loss for 2025 was - $2.9 million, an improvement of $3.6 million from the prior year . The net loss attributable to common shareholders was - $2,836,128 for 2025, compared to - $6,479,770 for 2024 . - **Adjusted Earnings**: Adjusted Earnings for the full year 2025 were $1.7 million, representing a $2.7 million improvement over the prior year . For 2025, Adjusted Earnings were $1,748,308, compared to - $990,865 for 2024 . - **Operating Expenses**: Total operating expenses for 2025 were $47.3 million, compared to $44,300,354 for 2024 . - **Operating Loss**: The operating loss for 2025 was - $2,791,993, an improvement from an operating loss of - $6,432,409 in 2024 . #### Cash Flow - **Cash Flow from Operations**: Cash flow from operations was $4.9 million in 2025, a $5.5 million increase over 2024 . Net cash provided by operating activities was $4,932,522 in 2025, compared to net cash used in operating activities of - $612,186 in 2024 . - **Net Cash from Investing Activities**: Net cash used in investing activities was - $4,706,497 in 2025, compared to net cash provided by investing activities of $57,842 in 2024 . - **Net Cash from Financing Activities**: Net cash used in financing activities was - $6,745,516 in 2025, compared to net cash provided by financing activities of $196,904 in 2024 . - **Cash and Cash Equivalents**: 坎伯兰药业 (Cumberland Pharmaceuticals Inc.) ended 2025 with $11,444,693 in cash and cash equivalents, a decrease from $17,964,184 at the beginning of the year . #### Balance Sheet - **Total Assets**: As of December 31, 2025, total assets were $76.8 million, compared to $75,583,410 at the end of 2024 . - **Total Liabilities**: Total liabilities were $52.3 million as of December 31, 2025, compared to $53,037,433 at the end of 2024 . - **Shareholders’ Equity**: Total shareholders’ equity was $24.9 million on December 31, 2025, compared to $22,853,494 at the end of 2024 . - **Debt Reduction**: The company’s credit facility balance of $5.2 million represented a reduction of $10 million in debt compared to the end of 2024 . #### Unique Metrics and Operational Highlights - **International Expansion**: 坎伯兰药业 (Cumberland Pharmaceuticals Inc.) received regulatory approval for its Vibativ® product in China in February 2025 and launched Vibativ in Saudi Arabia in September 2025 . Its ibuprofen injection product also received regulatory approval in Mexico in October 2025 . - **Commercial Portfolio Expansion**: In October 2025, the company announced a co-commercialization agreement with RedHill Biopharma Ltd. for Talicia®, an FDA-approved oral capsule for _H. pylori_ infection, adding it to its commercial product portfolio . - **Reimbursement Milestone**: Caldolor® received a permanent J-code (J1741) in December 2025, establishing a CMS reimbursement price that enhances provider access to this non-opioid pain and fever management option . - **Clinical Trial Results (ifetroban)**: Early 2025 saw positive top-line results from the FIGHT DMD clinical trial evaluating ifetroban for Duchenne muscular dystrophy (DMD) heart disease, showing a 3.3% overall improvement in left ventricular ejection fraction (LVEF) with high-dose ifetroban . The DMD program received Orphan Drug and Rare Pediatric Disease designations in late 2024 and Fast Track Designation in early 2026 from the FDA . #### Outlook / Guidance No specific outlook or guidance content was provided in the reference text . ### 相關股票 - [Cumberland Pharma (CPIX.US)](https://longbridge.com/zh-HK/quote/CPIX.US.md) ## 相關資訊與研究 - [Cipla expands U.S. respiratory portfolio with approval of nintedanib capsules (100mg & 150mg) for idiopathic pulmonary fibrosis](https://longbridge.com/zh-HK/news/281599098.md) - [Scinai Immunotherapeutics reports FY results](https://longbridge.com/zh-HK/news/281477360.md) - [Berenberg Lifts FY26 Estimates for Ferrari on Expected 'Strong' Q1](https://longbridge.com/zh-HK/news/281471058.md) - [BBVA Nears Halfway Mark in Second Tranche of Share Buyback as of Early April 2026](https://longbridge.com/zh-HK/news/281764185.md) - [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/zh-HK/news/281530653.md)